This inventor holds 65 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Cancer Treatment (CPC class 536 ). Top assignees: Gilead Sciences, Inc., Isis Pharmaceuticals, Inc., Threshold Pharmaceuticals, Inc.. Active years: 1990-2022.
Inventors with similar research interests:
Location History:
- San Francisco, CA (US) (1990 - 1991)
- Burkingue, CA (US) (2002)
- Burlingame, CA (US) (1992 - 2005)
- Portola Vall y, CA (US) (2005)
- Portolla Valley, CA (US) (2006)
- Redwood City, CA (US) (1990 - 2013)
- Portola Valley, CA (US) (1999 - 2020)
- Austin, TX (US) (2020)
- South San Francisco, CA (US) (2019 - 2022)
Company Filing History:
23 out of 946 
15 out of 1,035 
12 out of 19 
Years Active: 1990-2022
Areas of Expertise:
Title: Inventor Spotlight: Mark D Matteucci Revolutionizing Cancer Treatment
Introduction:
Mark D Matteucci, a prolific inventor based in Burlingame, CA, has made significant contributions to the field of oncology with a total of 65 patents under his name. His groundbreaking work in developing nitrobenzyl derivatives of anti-cancer agents has paved the way for innovative treatments in the fight against cancer.
Latest Patents:
Mark D Matteucci's latest patents focus on nitrobenzyl derivatives of anti-cancer agents. These compounds, as described in formula I, have shown promise in treating cancer by targeting specific pathways. The processes for their production and methods for administering these compounds represent a paradigm shift in cancer therapeutics.
Career Highlights:
During his career, Mark D Matteucci has worked with renowned companies such as Gilead Sciences, Inc., and Isis Pharmaceuticals, Inc. His tenure at these esteemed organizations has provided him with the platform to translate his innovative ideas into tangible solutions for cancer patients worldwide. His expertise and dedication have been instrumental in advancing the field of oncology.
Collaborations:
Mark D Matteucci has collaborated closely with notable peers in the industry, including Jian-Xin Duan and Kuei-Ying Lin. These collaborations have fostered a culture of innovation and knowledge-sharing, leading to the development of cutting-edge technologies aimed at improving cancer treatment outcomes.
Conclusion:
In conclusion, Mark D Matteucci stands out as a visionary inventor who has made remarkable contributions to cancer research through his inventive spirit and relentless pursuit of excellence. His patents, collaborations, and career highlights underscore his commitment to revolutionizing cancer treatment and bringing hope to patients battling this devastating disease.